Literature DB >> 23422487

Immunohistochemical and immunoelectron study of major histocompatibility complex class-II antigen in canine cutaneous histiocytoma: its relation to tumor regression.

Isabel Pires1, Paula Rodrigues, Anabela Alves, Felisbina Luisa Queiroga, Filipe Silva, Carlos Lopes.   

Abstract

In order to investigate the immune mechanisms involved in regression of canine cutaneous histicytoma (CCH), major histocompatibility complex (MHC) class-II immuno-expression and the number of T- and B-lymphocytes and macrophages were analyzed in 93 cases of CCH. MHC class-II was also studied in 16 cases of CCH by immunoelectron microscopy. All tumors expressed MHC class-II, and two major staining patterns were identified: focal juxtanuclear cytoplasmic staining and rim-like staining along the cell periphery. The MHC class-II labelling pattern and T- and B-lymphocyte infiltrates were associated with tumor regression. In regressing lesions, MHC class-II molecules shift to the cell surface and an increase of both T- and B-lymphocytes were noted. The increasing expression of MHC class-II molecules on the cell surface could be a significant factor for the onset and progression of tumour regression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23422487

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  2 in total

1.  A Role for Angiogenesis in Canine Cutaneous Histiocytoma Regression: Insights into an Old Clinical Enigma.

Authors:  Diana Costa; Rita Ferreira; Justina Prada; Felisbina Luisa Queiroga; Paula Rodrigues; Filipe Silva; Isabel Pires
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  Morphology and immunophenotype of canine cutaneous histiocytic tumours with particular emphasis on diagnostic application.

Authors:  Katarzyna Paździor-Czapula; Tadeusz Rotkiewicz; Iwona Otrocka-Domagała; Michał Gesek; Anna Śmiech
Journal:  Vet Res Commun       Date:  2014-11-25       Impact factor: 2.459

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.